Immunovant, Inc. Quarterly Deferred Tax Assets, Net of Valuation Allowance in USD from Q1 2019 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary
Immunovant, Inc. quarterly Deferred Tax Assets, Net of Valuation Allowance history and growth rate from Q1 2019 to Q1 2024.
  • Immunovant, Inc. Deferred Tax Assets, Net of Valuation Allowance for the quarter ending March 31, 2024 was $347K, a 30.9% decline year-over-year.
Deferred Tax Assets, Net of Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Net of Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2024 $347K -$155K -30.9% Mar 31, 2024 10-K 2024-05-29
Q1 2023 $502K -$128K -20.3% Mar 31, 2023 10-K 2024-05-29
Q1 2022 $630K -$204K -24.5% Mar 31, 2022 10-K 2023-05-22
Q1 2021 $834K +$791K +1840% Mar 31, 2021 10-K 2022-06-08
Q1 2020 $43K +$15K +53.6% Mar 31, 2020 10-K 2021-06-01
Q1 2019 $28K Mar 31, 2019 10-K 2020-06-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.